Avecia to double early phase
Avecia Pharmaceuticals is doubling its early phase pharmaceutical development and manufacturing capability in a US$50m (€57m) programme. The focus of the company's presence at Informex will be the recent expansion in the r&d facilities of its Canada-based pharmaceutical development business Torcan Chemical.
Complementing Torcan's capability for full service cGMP manufacturing, Avecia is building a new three-stream pilot plant in the UK for the rapid production of clinical trial quantities of intermediates.
Stand 1631